Search Results

For the in-vitro measurement for of IgG autoantibodies against B2-glycoprotein 1 (B2GP1) present in human serum. This kit may be used in conjunction with anticardiolipin assays and clinical information to aid the diagnosis of thrombosis in at risk patients having, for example, antiphospholipid syndrome (APS) or systemic lupus erythematosus (SLE).

Not Found

I am sorry, but based on the provided document, I cannot extract the detailed information required to describe the acceptance criteria and the study that proves the device meets those criteria. The document is a 510(k) clearance letter from the FDA, which confirms the substantial equivalence of the Bindazyme® Anti-B2 GP1 IgG EIA Test Kit to a predicate device for its stated indications for use.

While the document identifies the device and its intended use, it does not contain any information about:

• Specific acceptance criteria (thresholds or metrics) for the device's performance.
• Results of a study detailing performance metrics like sensitivity, specificity, accuracy, etc.
• Sample sizes for test or training sets.
• Data provenance.
• Details about experts establishing ground truth or adjudication methods.
• Whether MRMC or standalone studies were performed.
• Types of ground truth used.

Essentially, this document is a regulatory approval notice, not a detailed technical report of a performance study. To answer your request, I would need a different type of document, such as a summary of safety and effectiveness, a clinical study report, or a comprehensive device manual that includes performance data.

Ask a specific question about this device